Galecto Overview

  • Founded
  • 2011
Founded
  • Status
  • Public
  • Employees
  • 28
Employees
  • Stock Symbol
  • GLTO
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $3.91
  • (As of Monday Closing)

Galecto General Information

Description

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Contact Information

Website
www.galecto.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Primary Office
  • Ole Maaloes Vej 3
  • 2200 Copenhagen North
  • Denmark
+45 70 00 00 00

Galecto Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Galecto Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.91 $4.03 $3.80 - $17.99 $102M 25.3M 356K -$2.30

Galecto Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 18,450 412,606
Revenue 0 0 0 0
EBITDA (43,668) (34,649) (36,396) (12,899)
Net Income (48,875) (34,837) (36,507) (15,869)
Total Assets 146,822 171,596 56,609 35,104
Total Debt 1,088 915 298 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Galecto Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Galecto‘s full profile, request access.

Request a free trial

Galecto Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processe
Drug Discovery
Copenhagen North, Denmark
28 As of 2020
00000
0000 0000-00-00
00000000 00000

000000 0

quat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla p
0000000000000
San Francisco, CA
00 As of 0000
00000
000000000 00000

0000000

psum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolo
0000 000000000
Rockville, MD
00 As of 0000
000.00
000000000 - 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Galecto Competitors (53)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pliant Therapeutics Formerly VC-backed San Francisco, CA 00 00000 000000000 00000
0000000 Formerly VC-backed Rockville, MD 00 000.00 000000000 - 000.00
00000 000000000000 Formerly VC-backed Gosselies, Belgium 00 00000 00000000 00000
0000000000 0000000 Venture Capital-Backed Carmel, IN 0 00.000 000000 0
00000 000000000000 Formerly VC-backed South San Francisco, CA 00 00000 000000 - 000 00000
You’re viewing 5 of 53 competitors. Get the full list »

Galecto Executive Team (11)

Name Title Board Seat Contact Info
Hans Schambye Ph.D Chief Executive Officer & Board Member
Anders Pedersen Chief Operating Officer, Operations
Dorrit Andersen Director, Regulatory
Hakon Leffler Ph.D Co-Founder
Tariq Sethi Ph.D Co-Founder
You’re viewing 5 of 11 executive team members. Get the full list »

Galecto Board Members (19)

Name Representing Role Since
Amit Munshi Self Chairman & Board Member 000 0000
Anne Prener MD Self Board Member 000 0000
Carl Goldfischer MD PharmAkea Therapeutics Board Member 000 0000
Chandra Leo MD HBM Healthcare Investments Board Member 000 0000
Chau Khuong OrbiMed Board Member 000 0000
You’re viewing 5 of 19 board members. Get the full list »

Galecto Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Galecto Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Galecto‘s full profile, request access.

Request a free trial

Galecto Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 31-Dec-2019 000000000000000000 Biotechnology 0000 00000000 00.0
To view Galecto’s complete acquisitions history, request access »